Tango Therapeutics, Inc. SEC filings TNGX

Tango Therapeutics, Inc. has 424 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 17, 2026 —
DEF 14A Proxy statement Apr 17, 2026 Apr 16, 2026
DEFA14A Additional proxy material Apr 22, 2025 —
DEF 14A Proxy statement Apr 21, 2025 Apr 21, 2025
PRE 14A Preliminary proxy statement Apr 11, 2025 Apr 11, 2025
DEF 14A Proxy statement Apr 29, 2024 Dec 31, 2024
PRE 14A Preliminary proxy statement Apr 17, 2024 Jun 5, 2024
DEFA14A Additional proxy material Apr 24, 2023 —
DEF 14A Proxy statement Apr 24, 2023 Jun 6, 2023
DEFA14A Additional proxy material Apr 26, 2022 —
DEF 14A Proxy statement Apr 26, 2022 Jun 8, 2022

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TNGX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1819133
Former names
BCTG Acquisition Corp. (until Aug 9, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.